Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN significant upside
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(43)
•••
Post by Stockydocon Aug 17, 2022 4:03pm
117 Views
Post# 34903117

AGN significant upside

AGN significant upsideThis article from Medicalgold discusses AGN and why its improved fundamentals warrant a much higher valuation. Here's some details:

- AGN's strategy focuses on drug repurposing resulting in a lower risk of failure, reduced R&D costs, and a quicker time to market (6.5 yrs compared to 12-16 yrs)

- Discusses Ifenprodil which AGN is repurposing for idiopathic pulmonary fibrosis (IPF) and chronic cough

- Provides update on the phase 1 study for DMT in which researchers observed a statistically significant 40% increase in response to DMT treatment compared to control

- Lists upcoming catalysts including the pre-IND meeting for Phase 2b for Ifenprodil, attaining orphan drug designation for Ifenprodil, filing an application with the FDA for breakthrough therapy designation, and more

Looking at the technicals for AGN, shares were oversold in mid-July but have rebounded and could experience significant upside of 50-100% by the end of the year. AGN currently sits @ $4 (+10.50%) today.

https://www.medicalgold.ca/featured/algernon-human-clinical-trials-update
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities